Serum hypoalbuminemia predicts late mortality on the liver transplant waiting list

Transplantation

Volumn 99, Issue 1, 2015, Pages 158-163

  Porrett, Paige M ^a   Baranov, Esther ^a   Ter Horst, Matthijs ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALB PROTEIN, HUMAN; BIOLOGICAL MARKER; SERUM ALBUMIN;

ADULT; ARTICLE; CAUSE OF DEATH; FEMALE; HEALTH CARE ACCESS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPOALBUMINEMIA; INTENTION TO TREAT ANALYSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL FACTOR; SURVIVAL PREDICTION; SURVIVOR; BLOOD; DECISION SUPPORT SYSTEM; DOWN REGULATION; KAPLAN MEIER METHOD; LIVER DISEASES; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME;

BIOLOGICAL MARKERS; DECISION SUPPORT TECHNIQUES; DOWN-REGULATION; FEMALE; HUMANS; HYPOALBUMINEMIA; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; WAITING LISTS;

EID: 84920263565     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000299     Document Type: Article

References (26)

1. Freeman RB, Wiesner RH, Edwards E, et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004;10:7.
2. http://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&tpl=/ecfrbrowse/Title42/ 42cfr121-main-02.tpl.
3. Anonymous. Organ procurement and transplantation network - HRSA. Final rule with comment period. Fed Regist 1998;63:16296.
4. http://optn.transplant.hrsa.gov/CommitteeReports/board-main-Membership&Prof. StandardsCommittee(MPSC)-11-24-2009-11-54.pdf.
5. Sharma P, Schaubel DE, Sima CS, et al. Re-weighting the model for endstage liver disease score components. Gastroenterology 2008;136: 1676.
6. LeiseMD, KimWR, KremersWK, et al. A revisedmodel for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011;140:1952.
7. Myers RP, Shaheen A, Faris P, et al. Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS One 2013; 8: e51926.
8. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018.
9. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR). Annual Data Report, 2011. http:// srtr.transplant.hrsa.gov/annual-reports/2011/default.aspx.
10. Voigt MD, Hunsicker LG, Snyder JJ, et al. Regional variability in liver waiting list removals causes false ascertainment of wait list deaths. Am J Transplant 2013;13:369.
11. Goldberg D, French B, Trotter J, et al. Underreporting of liver transplant wait list removals due to death or clinical deterioration: results at four major centers. Transplantation 2013;96:211.
12. Gotthardt D, Weiss KH, Baumgartner M, et al. Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol 2009;9:72
13. Somsok M, Kornfield R, Vittinghoff E, et al. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transplantation 2011;17:129.
14. Child CD, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The liver and portal hypertension. Philadelphia: Saunders; 1964:50.
15. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864.
16. Boldt J. Use of albumin: an update. Br J Anaesth 2010;3:276.
17. Margarson MP, Soni SC. Changes in serum albumin concentration and volume expanding effects following a bolus of albumin 20% in septic patients. Br J Anaesth 2004;92:821.
18. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000;85:599.
19. Garcia-Martinez R, Caraceni P, BernardiM, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013;58:1836.
20. Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis are associated with increased mortality. Hepatology 2009;50:555.
21. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91.
22. Washburn K. Model for end stage liver disease and hepatocellular carcinoma: a moving target. Transplant Rev 2010;24:11.
23. Schaubel DE, Sima CS, Goodrich NP, et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008;8:419.
24. UNET Reference form: "Liver candidate Add/Edit Field Descriptions". https://www.unet.unos.org/Help/netscape-waitlist/Liver-candidate.htm. Downloaded 03/17/2104.
25. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087.
26. Vincent J-L, Dubois M-J, Navickis RJ, et al. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg 2003;237:319.